Prodigiosin and its derivatives as new options for melanoma treatment (2017)
Fonte: Brazilian Journal of Pharmaceutical Sciences. Nome do evento: Workshop on Melanoma Models. Unidades: FCFRP, FCF, ICB
Assunto: MELANOMA
ABNT
BRANCO, Paola Cristina et al. Prodigiosin and its derivatives as new options for melanoma treatment. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 03 out. 2024. , 2017APA
Branco, P. C., Pontes, C. A., Bauermeister, A., Fernandes, D. K. A., Hirata, A. S., Jimenez, P. C., et al. (2017). Prodigiosin and its derivatives as new options for melanoma treatment. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo.NLM
Branco PC, Pontes CA, Bauermeister A, Fernandes DKA, Hirata AS, Jimenez PC, Lopes NP, Maria-Engler SS, Costa-Lotufo LV. Prodigiosin and its derivatives as new options for melanoma treatment. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 28 res. WM-031.[citado 2024 out. 03 ]Vancouver
Branco PC, Pontes CA, Bauermeister A, Fernandes DKA, Hirata AS, Jimenez PC, Lopes NP, Maria-Engler SS, Costa-Lotufo LV. Prodigiosin and its derivatives as new options for melanoma treatment. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 28 res. WM-031.[citado 2024 out. 03 ]